PTC Therapeutics, Inc. (PTCT)
$
69.45
-1.25 (-1.80%)
Key metrics
Financial statements
Free cash flow per share
8.5770
Market cap
5.6 Billion
Price to sales ratio
3.1341
Debt to equity
-15.9995
Current ratio
2.3178
Income quality
0.9518
Average inventory
43.4 Million
ROE
-1.8266
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
PTC Therapeutics, Inc. is a biopharmaceutical company that specializes in the discovery, development, and commercialization of medicines for patients with rare disorders. Its portfolio includes a range of commercial products and candidates at various development stages, focusing on therapeutic areas such as rare diseases. The company’s offerings, including Translarna and Emflaza, serve patients with Duchenne muscular dystrophy in the European Economic Area and the United States, and address nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. Additionally, PTC Therapeutics commercializes Tegsedi and Waylivra for rare diseases in Latin America and the Caribbean, while Evrysdi is marketed for spinal muscular atrophy treatment in individuals aged two months and older in Brazil. The firm's innovative splicing platform features PTC518, currently being developed for Huntington's disease. The diluted EPS is -$4.73 accounting for potential share dilution. The net total of other income and expenses is -$60,549,000.00 reflecting non-core financial activities. The weighted average number of shares outstanding is $76,845,055.00 highlighting the company's shareholder base. The company's stock is identified with the symbol '$PTCT' in the market, and the financial data pertains to the fiscal year $2024. PTC Therapeutics maintains collaborations with notable entities such as F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to further drug discovery and development research in regenerative medicine, along with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra. At an affordable price of $60.48 the stock is suitable for budget-conscious investors. With an average trading volume of $1,581,521.00 the stock indicates moderate liquidity, providing investors ease of entry and exit. The company possesses a mid-range market capitalization of $5,576,022,435.00 positioning it as a steady performer within the biopharmaceutical landscape. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Furthermore, PTC Therapeutics belongs to the Healthcare sector, driving both innovation and growth in therapeutic development.
Is PTC Therapeutics, Inc. (PTCT) a good investment?
Investing in PTC Therapeutics, Inc. (PTCT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is PTC Therapeutics, Inc. (PTCT)'s stock forecast?
Analysts predict PTC Therapeutics, Inc. stock to fluctuate between $35.95 (low) and $87.50 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is PTC Therapeutics, Inc.'s market capitalization?
As of 2026-02-13, PTC Therapeutics, Inc.'s market cap is $5,576,022,435, based on 80,288,300 outstanding shares.
How does PTC Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., PTC Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy PTC Therapeutics, Inc. (PTCT) stock?
To buy PTC Therapeutics, Inc. (PTCT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for PTCT. Place an order (Market, Limit, etc.).
What is the best time to invest in PTC Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did PTC Therapeutics, Inc. perform in the last earnings report?
Revenue: $806,780,000 | EPS: -$4.73 | Growth: -43.49%.
Where can I find PTC Therapeutics, Inc.'s investor relations reports?
Visit https://www.ptcbio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for PTC Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for PTC Therapeutics, Inc. stock?
All-time high: $87.50 (2025-11-26) | All-time low: $17.53 (2023-11-02).
What are the key trends affecting PTC Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
PTC Therapeutics, Inc. (PTCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
defenseworld.net
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) CFO Pierre Gravier sold 2,139 shares of the business's stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $76.95, for a total value of $164,596.05. Following the completion of the sale, the chief financial officer owned 90,310
seekingalpha.com
PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
seekingalpha.com
PTC Therapeutics, Inc. (PTCT) Discusses Progress in Small Molecule Splicing and Ferroptosis Platforms Transcript
fool.com
Emma Reeve recently exercised some PTC Therapeutics stock options and sold the shares immediately. Reeve is an independent board director at PTC Therapeutics.
seekingalpha.com
PTC Therapeutics, Inc. ( PTCT ) UBS Global Healthcare Conference 2025 November 11, 2025 3:30 PM EST Company Participants Matthew Klein - CEO & Director Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division All right. Good day, everybody.
seekingalpha.com
PTC Therapeutics, Inc. ( PTCT ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Ellen Cavaleri Matthew Klein - CEO & Director Eric Pauwels - Chief Business Officer Pierre Gravier - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Tazeen Ahmad - BofA Securities, Research Division Brian Abrahams - RBC Capital Markets, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Judah Frommer - Morgan Stanley, Research Division Yuxi Dong - Jefferies LLC, Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Joon Lee - Truist Securities, Inc., Research Division Huidong Wang - Barclays Bank PLC, Research Division Samantha Corwin - William Blair & Company L.L.C., Research Division Joseph Schwartz - Leerink Partners LLC, Research Division John Peyton Bohnsack - TD Cowen, Research Division Luke Herrmann - Robert W.
zacks.com
PTC Therapeutics (PTCT) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of a loss of $1.19 per share. This compares to a loss of $1.39 per share a year ago.
seekingalpha.com
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 9:15 AM EDT Company Participants Matthew Klein - CEO & Director Pierre Gravier - Chief Financial Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst All right. Welcome, everyone, to this session of the Morgan Stanley Global Healthcare Conference.
seekingalpha.com
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Cantor Global Healthcare Conference 2025 September 3, 2025 8:35 AM EDT Company Participants Matthew Klein - CEO & Director Pierre Gravier - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Presentation Kristen Kluska Analyst Hi, good morning, everybody. I'm Kristen Kluska, one of the biotech analysts at Cantor.
See all news
